Veracyte VCYT Biopharmaceutical and other revenue — Deferred Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.
The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Veracyte's biopharmaceutical and other revenue — deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Veracyte's biopharmaceutical and other revenue — deferred revenue?
- Veracyte (VCYT) reported biopharmaceutical and other revenue — deferred revenue of $700K in Q1 2026.
- How has Veracyte's biopharmaceutical and other revenue — deferred revenue changed year-over-year?
- Veracyte's biopharmaceutical and other revenue — deferred revenue decreased by 58.8% year-over-year, from $1.7M to $700K.
- What is the long-term trend for Veracyte's biopharmaceutical and other revenue — deferred revenue?
- Over 3 years (2022 to 2025), Veracyte's biopharmaceutical and other revenue — deferred revenue has grown at a -32.1% compound annual growth rate (CAGR), from $15.3M to $4.8M.
- What does biopharmaceutical and other revenue — deferred revenue mean?
- This metric reflects payments received from biopharmaceutical partners for services or milestones that have not yet been fully performed or satisfied under contract terms. It provides insight into future revenue recognition and the company's ability to secure upfront funding for long-term research projects.